Figure 1 from Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K–Mutant Advanced or Metastatic Melanoma

Read full text Summarise with VIRAT
Authors: Reinhard Dummer, Shibing Deng, Tao Xie, Nuzhat I. Pathan, Hedieh Saffari, Caroline Robert, Ana Arance, Jan Willem B. de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová
+11 more Gabriella Liszkay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Paolo A. Ascierto, Craig B. Davis, Khyati Niral Shah, Phineas T. Hamilton, Alessandra di Pietro, Keith T. Flaherty
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PFS and OS for encorafenib plus binimetinib or encorafenib vs. vemurafenib by (A and B) TMB and (C and D) cytolytic score. E, Volcano plots of univariable gene expression associations with OS in each arm based on z-scored gene expression values. F, Gene-set enrichment analysis of gene expression associations against hallmark gene signatures; signatures with greatest average NES across arms shown. Bini, binimetinib; BM, biomarker; CYT, cytotoxic score; Enco, encorafenib; NES, normalized enrichment scores; Vemu, vemurafenib.

Fields of Study & Subjects

Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers Cutaneous Melanoma Detection and Management

Publication details

Publication date
1 April 2026
Language
EN